Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets.

Abstract excerpt

For decades, therapy for advanced melanoma has lagged behind most of the cancer field owing to its intrinsic resistance to conventional cytotoxic chemotherapy and limited impact of cytokine-based immunotherapy. The opportunity to develop molecularly targeted therapy emerged with the discovery of activating mutations in BRAF, a component of the long studied MAP kinase pathway. These mutations are found in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Imidazoles
• Share to Indoles
• Share to Mitogen-Activated Protein Kinases